Improving ELISA-Based Host Cell Protein Detection for Biologic Production

Scientists manufacturing biological drugs (biologics), such as monoclonal antibodies or therapeutic proteins, must ensure that they removed all cell culture-related impurities, including host cell proteins (HCPs), from their samples. To do this, they perform ELISAs with specialized polyclonal antibodies, but must first determine the assay’s sensitivity to cell line-specific HCPs by doing a coverage analysis on cells that don’t express the biologic. However, when the original cell line is unavailable, coverage analysis becomes complicated because the biologic’s high concentration masks a subset of HCPs.

Watch this webinar from Cytiva to learn

  • How the presence of a biologic alters coverage analysis
  • How to perform coverage analysis when a control cell line is unavailable
  • How to clear a biologic from a sample to improve coverage analysis

Source link

Leave a Comment

Your email address will not be published. Required fields are marked *